Literature DB >> 25683870

Falsified antimalarials: a minireview.

Carlos Chaccour1, Harparkash Kaur, Jose Luis Del Pozo.   

Abstract

Malaria is a curable disease, provided timely access to efficacious drugs is sought. Poor quality and, in particular, falsified antimalarial drugs harm the population of malaria endemic areas; they put lives in peril, cause economic losses to patients, families, industry, and generally undermine the trust in health systems. The extent of the problem is not easily assessed, and although a prevalence of up to 35% of poor-quality antimalarials has been reported, this number should be interpreted with caution given the heterogeneity of methods used to measure it. The trade in falsified antimalarials can be curtailed by putting in place drug quality surveillance, better legislation and improving the access and affordability of these essential drugs.

Entities:  

Keywords:  antimalarials; artemisinin; artesunate; counterfeit drugs; falsified drugs; malaria; poor-quality drugs; substandard drugs

Mesh:

Substances:

Year:  2015        PMID: 25683870     DOI: 10.1586/14787210.2015.1015990

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  8 in total

1.  Assessing the quality of anti-malarial drugs from Gabonese pharmacies using the MiniLab®: a field study.

Authors:  Benjamin J Visser; Janneke Meerveld-Gerrits; Daniëlle Kroon; Judith Mougoula; Rieke Vingerling; Emmanuel Bache; Jimmy Boersma; Michèle van Vugt; Selidji T Agnandji; Harparkash Kaur; Martin P Grobusch
Journal:  Malar J       Date:  2015-07-15       Impact factor: 2.979

2.  Prevalence of substandard and falsified artemisinin-based combination antimalarial medicines on Bioko Island, Equatorial Guinea.

Authors:  Harparkash Kaur; Elizabeth Louise Allan; Ibrahim Mamadu; Zoe Hall; Michael D Green; Isabel Swamidos; Prabha Dwivedi; Maria Julia Culzoni; Facundo M Fernandez; Guillermo Garcia; Dianna Hergott; Feliciano Monti
Journal:  BMJ Glob Health       Date:  2017-10-15

3.  Poor-quality antimalarials further health inequities in Uganda.

Authors:  Daniel R Evans; Colleen R Higgins; Sarah K Laing; Phyllis Awor; Sachiko Ozawa
Journal:  Health Policy Plan       Date:  2019-12-01       Impact factor: 3.344

4.  Blind-Watermarking-Proof-of-Concept of a Novel Approach to Ensure Batch Traceability for 3D Printed Tablets.

Authors:  Hellen Windolf; Rebecca Chamberlain; Arnaud Delmotte; Julian Quodbach
Journal:  Pharmaceutics       Date:  2022-02-17       Impact factor: 6.321

5.  Substandard and falsified medical products: bibliometric analysis and mapping of scientific research.

Authors:  Waleed M Sweileh
Journal:  Global Health       Date:  2021-09-23       Impact factor: 4.185

6.  The diagnostic accuracy of the hand-held Raman spectrometer for the identification of anti-malarial drugs.

Authors:  Benjamin J Visser; Sophia G de Vries; Emmanuel B Bache; Janneke Meerveld-Gerrits; Daniëlle Kroon; Jimmy Boersma; Selidji T Agnandji; Michèle van Vugt; Martin P Grobusch
Journal:  Malar J       Date:  2016-03-15       Impact factor: 2.979

7.  Are we doing enough to prevent poor-quality antimalarial medicines in the developing world?

Authors:  Erin J Walker; Gregory M Peterson; James Grech; Evie Paragalli; Jackson Thomas
Journal:  BMC Public Health       Date:  2018-05-15       Impact factor: 3.295

8.  Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.

Authors:  Sachiko Ozawa; Daniel R Evans; Sophia Bessias; Deson G Haynie; Tatenda T Yemeke; Sarah K Laing; James E Herrington
Journal:  JAMA Netw Open       Date:  2018-08-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.